Hearing the Hoofbeats of Pheochromocytoma in New-Onset Cardiomyopathy Leads to Success Instead of Failure.

Michelle Dimza, Ananya Gorrai, Liwei Jia, Robert M Morlend, Mark H Drazner

Abstract readCase Reports

In one paragraph

Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michelle DimzaDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Ananya GorraiDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Liwei JiaDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Robert M MorlendDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Mark H DraznerDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: mark.drazner@utsouthwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pheochromocytoma is a rare cause of nonischemic cardiomyopathy with a variable clinical presentation. We report 2 cases in which the diagnosis of pheochromocytoma was not initially recognized during evaluation of a reduced left ventricular ejection fraction, despite some potential clues. Following diagnosis, largely driven by incidental detection of an adrenal mass, targeted treatment with surgical resections led to successful outcomes. One patient maintained left ventricular ejection fraction >55% for more than 15 years. These cases emphasize that in patients with new-onset nonischemic cardiomyopathy who have either a relapsing/remitting pattern of left ventricular ejection fraction or evidence of catecholamine excess, pheochromocytoma should be considered. With appropriate diagnosis and targeted treatment, successful and durable recovery of cardiac function is possible.

Indexed as

acute heart failurecardiomyopathyejection fractionreduced ejection fractionrisk factorsystolic heart failure

Identifiers

PMID40816841

DOI10.1016/j.jaccas.2025.104443

PMCPMC12462128

What Socratic holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.